High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
AV Hirayama, J Gauthier, KA Hay… - Blood, The Journal …, 2019 - ashpublications.org
Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …
refractory disease, or histologic transformation (tFL) have limited progression-free and …
[HTML][HTML] High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu… - Blood, 2019 - Elsevier
Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …
refractory disease, or histologic transformation (tFL) have limited progression-free and …
[HTML][HTML] High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu… - Blood, 2019 - ncbi.nlm.nih.gov
Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …
refractory disease, or histologic transformation (tFL) have limited progression-free and …
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu… - Blood, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Patients with follicular lymphoma (FL) with
early relapse after initial chemoimmunotherapy, refractory disease, or histologic …
early relapse after initial chemoimmunotherapy, refractory disease, or histologic …
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu… - Blood, 2019 - europepmc.org
Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …
refractory disease, or histologic transformation (tFL) have limited progression-free and …
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …
refractory disease, or histologic transformation (tFL) have limited progression-free and …
[引用][C] HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY
AV Hirayama, J Gauthier, KA Hay… - Hematological …, 2019 - Wiley Online Library
Methods: We conducted a phase 1/2 clinical trial (NCT01865617) of CD19 CAR-T cell
immunotherapy in adults with relapsed/refractory (R/R) CD19+ B-cell malignancies. Best …
immunotherapy in adults with relapsed/refractory (R/R) CD19+ B-cell malignancies. Best …
High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu… - Blood, 2019 - europepmc.org
Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy,
refractory disease, or histologic transformation (tFL) have limited progression-free and …
refractory disease, or histologic transformation (tFL) have limited progression-free and …